

Leandro Cerchietti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7472017/publications.pdf>

Version: 2024-02-01

118
papers

6,701
citations

71102

41
h-index

64796

79
g-index

122
all docs

122
docs citations

122
times ranked

10652
citing authors

#	ARTICLE	IF	CITATIONS
1	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	16.8	706
2	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8368-8373.	7.1	286
3	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. <i>Nature Medicine</i> , 2004, 10, 1329-1335.	30.7	272
4	A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. <i>Cancer Cell</i> , 2010, 17, 400-411.	16.8	263
5	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , 2011, 7, 818-826.	8.0	240
6	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	27.8	233
7	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo. <i>Cancer Cell</i> , 2012, 22, 812-824.	16.8	229
8	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548.	1.4	205
9	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. <i>Cancer Discovery</i> , 2013, 3, 1002-1019.	9.4	180
10	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR/ABL1 kinase inhibition. <i>Nature</i> , 2011, 473, 384-388.	27.8	174
11	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. <i>Nature</i> , 2014, 511, 90-93.	27.8	168
12	A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters. <i>Cell Reports</i> , 2013, 4, 578-588.	6.4	161
13	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 2163-2174.	8.5	154
14	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6 dependent B cell lymphomas. <i>Nature Medicine</i> , 2009, 15, 1369-1376.	30.7	149
15	Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer. <i>Molecular Cell</i> , 2008, 29, 384-391.	9.7	144
16	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89.	1.4	138
17	Limits in the detection of m6A changes using MeRIP/m6A-seq. <i>Scientific Reports</i> , 2020, 10, 6590.	3.3	136
18	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3351-3362.	8.2	133

#	ARTICLE	IF	CITATIONS
19	Histone deacetylase inhibitor treatment induces β -BRCAness™ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. <i>Oncotarget</i> , 2014, 5, 5637-5650.	1.8	131
20	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3207-3212.	7.1	130
21	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , 2011, 118, 3559-3569.	1.4	123
22	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021, 11, 1468-1489.	9.4	119
23	The Bcl6-SMRT/NCOR Cistrome Represses Inflammation to Attenuate Atherosclerosis. <i>Cell Metabolism</i> , 2012, 15, 554-562.	16.2	111
24	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921.	12.8	111
25	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , 2010, 207, 1209-1221.	8.5	108
26	Ex Vivo engineered immune organoids for controlled germinal center reactions. <i>Biomaterials</i> , 2015, 63, 24-34.	11.4	108
27	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	3.5	102
28	MiR-592 Regulates the Induction and Cell Death-Promoting Activity of p75 ^{NTR} in Neuronal Ischemic Injury. <i>Journal of Neuroscience</i> , 2014, 34, 3419-3428.	3.6	82
29	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , 2016, 127, 858-868.	1.4	76
30	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , 2013, 121, 5192-5202.	1.4	75
31	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. <i>Nature Genetics</i> , 2017, 49, 866-875.	21.4	75
32	Integrin α _v β ₃ acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. <i>Blood</i> , 2015, 125, 841-851.	1.4	74
33	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. <i>Nature Communications</i> , 2017, 8, 14290.	12.8	74
34	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. <i>Cancer Cell</i> , 2019, 35, 916-931.e9.	16.8	70
35	Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. <i>Biomaterials</i> , 2015, 73, 110-119.	11.4	66
36	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2020, 30, 755-770.e6.	6.4	65

#	ARTICLE	IF	CITATIONS
37	Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. <i>Blood</i> , 2013, 122, 2837-2847.	1.4	64
38	Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. <i>Blood</i> , 2011, 118, 4174-4178.	1.4	58
39	Germline Lysine-Specific Demethylase 1 (<i>LSD1/KDM1A</i>) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759.	0.9	56
40	Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 192-196.	0.4	53
41	Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas. <i>PLoS ONE</i> , 2011, 6, e18436.	2.5	45
42	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. <i>Cancer Discovery</i> , 2017, 7, 506-521.	9.4	43
43	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. <i>Cellular and Molecular Bioengineering</i> , 2014, 7, 394-408.	2.1	37
44	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4559-4571.	8.2	37
45	Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. <i>Cancer Research</i> , 2017, 77, 3070-3081.	0.9	36
46	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. <i>Clinical Epigenetics</i> , 2016, 8, 79.	4.1	35
47	BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 295-295.	1.4	34
48	BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. <i>Cancer Discovery</i> , 2019, 9, 662-679.	9.4	31
49	The eukaryotic translation initiation factor eIF4E elevates steady-state m ⁷ G capping of coding and noncoding transcripts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26773-26783.	7.1	29
50	Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. <i>Breast Cancer Research</i> , 2014, 16, 491.	5.0	27
51	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 3520-3532.	1.8	26
52	Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. <i>EBioMedicine</i> , 2018, 28, 80-89.	6.1	25
53	Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer. <i>ACS Chemical Biology</i> , 2014, 9, 1698-1705.	3.4	23
54	Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner. <i>Journal of Biomedical Materials Research - Part A</i> , 2017, 105, 1833-1844.	4.0	23

#	ARTICLE	IF	CITATIONS
55	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , 2013, 122, 1-1.	1.4	23
56	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. <i>Oncotarget</i> , 2016, 7, 79637-79653.	1.8	21
57	The metabolism of lymphomas. <i>Current Opinion in Hematology</i> , 2013, 20, 345-354.	2.5	19
58	Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 591-595.	2.5	19
59	The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases. <i>Science Advances</i> , 2021, 7, eabg1964.	10.3	18
60	Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. <i>Expert Review of Hematology</i> , 2013, 6, 343-345.	2.2	17
61	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.	1.4	17
62	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216.	0.9	14
63	Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. <i>Blood Cancer Discovery</i> , 2022, 3, 50-65.	5.0	14
64	Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. <i>Cancer Research</i> , 2017, 77, 1818-1830.	0.9	13
65	High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells. <i>Cancer Letters</i> , 2015, 368, 97-104.	7.2	12
66	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
67	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. <i>Blood</i> , 2011, 118, 3725-3725.	1.4	11
68	Variational autoencoders learn transferrable representations of metabolomics data. <i>Communications Biology</i> , 2022, 5, .	4.4	11
69	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. <i>Blood</i> , 2009, 114, 619-619.	1.4	10
70	SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75Åyears or older with newly diagnosed aggressive non-Hodgkin lymphomas â€“ Aiming to improve therapy, outcomes, and validate a prospective frailty tool. <i>Journal of Geriatric Oncology</i> , 2022, 13, 258-264.	1.0	9
71	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2020, 10, 13094.	3.3	8
72	Design and Development of Small Molecules for Specific Targeted Therapy of Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2007, 110, 799-799.	1.4	8

#	ARTICLE	IF	CITATIONS
73	DNA Methylation-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2017, 35, 793-795.	1.6	7
74	The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. <i>Leukemia and Lymphoma</i> , 2018, 59, 256-258.	1.3	7
75	Thyroid hormones induce doxorubicin chemosensitivity through enzymes involved in chemotherapy metabolism in lymphoma T cells. <i>Oncotarget</i> , 2019, 10, 3051-3065.	1.8	7
76	Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. <i>Blood</i> , 2019, 134, 656-656.	1.4	6
77	The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. <i>Blood</i> , 2013, 122, 781-781.	1.4	6
78	Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. <i>Cell Cycle</i> , 2016, 15, 2241-2247.	2.6	5
79	Histamine H4 Receptor Agonism Induces Antitumor Effects in Human T-Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1378.	4.1	5
80	Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2688-2693.	2.5	4
81	Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). <i>Blood</i> , 2018, 132, 2964-2964.	1.4	4
82	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 446-446.	1.4	4
83	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. <i>Haematologica</i> , 2021, , .	3.5	3
84	Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 5-5.	1.4	3
85	BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain. <i>Blood</i> , 2014, 124, 567-567.	1.4	3
86	A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2020, 136, 7-8.	1.4	3
87	Personalized Epigenetic Therapy-Chemosensitivity Testing. , 2015, , 667-676.		2
88	BCL6 Inhibitor Peptide Have Powerful Anti-Lymphoma Activity in Animal Models of Diffuse Large B-Cell Lymphoma and Synergize with Other Anti-Lymphoma Drugs.. <i>Blood</i> , 2006, 108, 827-827.	1.4	2
89	Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL. <i>Blood</i> , 2012, 120, 3706-3706.	1.4	2
90	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 634-634.	1.4	2

#	ARTICLE	IF	CITATIONS
91	A Virtual B Cell Lymphoma Model to Predict Effective Combination Therapy. <i>Blood</i> , 2014, 124, 928-928.	1.4	2
92	BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2167-2167.	1.4	2
93	<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. <i>Cancer Discovery</i> , 0, , OF1-OF20.	9.4	2
94	Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 218-221.	1.3	1
95	DNA Methyltransferase 1 Contributes to Epigenetic Signatures and Biological Phenotype during Normal B-Cell Differentiation and Lymphomagenesis.. <i>Blood</i> , 2007, 110, 685-685.	1.4	1
96	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 202-202.	1.4	1
97	Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL.. <i>Blood</i> , 2007, 110, 523-523.	1.4	1
98	BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.. <i>Blood</i> , 2009, 114, 91-91.	1.4	1
99	Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 64-64.	1.4	1
100	Serum Metabolomics Uncovers a New Therapeutic Target in Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2012, 120, 1648-1648.	1.4	1
101	Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. <i>Blood</i> , 2014, 124, 1764-1764.	1.4	1
102	Sensitivity of Diffuse Large B-Cell Lymphomas to DNA Methyltransferase Inhibitors Is Associated with a Specific Epigenetic Signature.. <i>Blood</i> , 2006, 108, 831-831.	1.4	0
103	BCL6 Regulates Diffuse Large B-Cell Lymphoma Cell Cycle and Apoptosis Checkpoints through Direct Repression of the p300 Histone Acetyl-Transferase.. <i>Blood</i> , 2006, 108, 1413-1413.	1.4	0
104	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 616-616.	1.4	0
105	Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma. <i>Blood</i> , 2008, 112, 602-602.	1.4	0
106	BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 765-765.	1.4	0
107	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. <i>Blood</i> , 2010, 116, 705-705.	1.4	0
108	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , 2011, 118, 1617-1617.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. Blood, 2011, 118, 1406-1406.	1.4	0
110	Thyroid Hormones Maintain The CTCL Malignant Phenotype Through Membrane- and Nuclear-Initiated Transcriptional Programs. Blood, 2013, 122, 3810-3810.	1.4	0
111	A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. Blood, 2013, 122, 821-821.	1.4	0
112	Unbiased Pharmacological Screening Identified New Therapeutic Strategies For Peripheral T-Cell Lymphomas (PTCLs). Blood, 2013, 122, 4423-4423.	1.4	0
113	Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL. Blood, 2013, 122, 4339-4339.	1.4	0
114	Integrin $\alpha 5 \beta 3$ Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target. Blood, 2014, 124, 510-510.	1.4	0
115	Transcription Regulation Targeting in Peripheral T Cell Lymphomas Induces Apoptosis and Sensitization to BCL2 Inhibitors. Blood, 2014, 124, 810-810.	1.4	0
116	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. Blood, 2017, 130, 645-645.	1.4	0
117	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. Blood, 2018, 132, 2854-2854.	1.4	0
118	XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells. Blood, 2020, 136, 18-18.	1.4	0